Dr. Lance Feller is a board-certified rheumatologist with rare dual fellowship training in both adult and pediatric rheumatology — a distinction that uniquely positions him to care for patients across the full spectrum of rheumatic disease. He has a particular interest in adults living with conditions that began in childhood, and in helping adolescents navigate the transition from pediatric to adult rheumatologic care.

Before joining Central Florida Rheumatology Consultants, Dr. Feller served as Medical Director at Inland Rheumatology in Maine and as Assistant Professor at the University of Central Florida College of Medicine, where he trained rheumatology fellows and served as Site Director for their fellowship program. He is a Fellow of the American College of Rheumatology (FACR), a former member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and a member of the National Med-Peds Residents' Association (NMPRA).

Clinical Expertise

Dr. Feller specializes in the diagnosis and management of juvenile idiopathic arthritis, systemic lupus erythematosus, scleroderma, inflammatory arthritis, and complex autoimmune conditions in both adult and pediatric populations. He is experienced in biologic therapies and advanced disease-modifying treatment strategies.

Education & Training

• Rheumatology Fellowship (Adult & Pediatric) — Saint Louis University School of Medicine
• Dual Residency, Internal Medicine & Pediatrics — Newark Beth Israel Medical Center, NJ
• MD — St. George's University School of Medicine
• BS, Biochemistry, Cell Biology & Psychology — University of California, San Diego

Board Certification

• Board-Certified in Rheumatology — American Board of Internal Medicine
• Fellow, American College of Rheumatology (FACR)

Philosophy of Care

Dr. Feller is committed to evidence-based, individualized care that meets patients where they are — whether that means bridging the gap from adolescence to adulthood or managing a complex condition that has evolved over a lifetime.

Research & Publications

Dr. Feller is an active researcher with a focus on biomarkers in juvenile idiopathic arthritis and rare or atypical rheumatologic presentations. His work has been published in peer-reviewed journals and presented at major national and international conferences including the ACR/ARHP Annual Scientific Meeting, the Pediatric Rheumatology Symposium (PRSYM), and the Congress of Clinical Rheumatology.

1. Dalrymple A, Tuttle P, Feller L, Zhukov O, Lagier R, Popov J, Naides S, Moore TL. 14-3-3 eta Protein as a Potential Biomarker in Juvenile Idiopathic Arthritis. Pediatr. Rep. 2021, 13(1), 65-71; https://doi.org/10.3390/pediatric13010008

2. Moore T, Dalrymple A, Feller L, Tuttle P. Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/minor-biomarkers-in-juvenile-idiopathic-arthritis-jia/. Accessed November 18, 2020.

3. Chawla A, Vuyyuru S, Feller L. Favorably Unfavorable: Interstitial Lung Disease as the Initial Manifestation of Anti-Mi-2 Positive Dermatomyositis. Ann Arthritis Clin Rheumatol. 2020; 3(1): 1019.

4. Chawla A, Macias KC, Vuyyuru S, Gros B, Feller L. Elevated Alkaline Phosphatase: The initial laboratory abnormality in an atypical presentation of Takayasu arteritis. Int. J. Clin. Rheumatol. (2020) 15(2), 33-36.

5. Chawla A, Vuyyuru S, Feller L. Favorably Unfavorable: Interstitial Lung Disease as the Initial Manifestation of Anti-Mi-2 Positive Dermatomyositis [abstract]. (Presented Congress of Clinical Rheumatology, San Diego CA, September 2019).

6. Chawla A, Macias KC, Vuyyuru S, Gros B, Feller L. Elevated Alkaline Phosphatase: The Initial Laboratory Abnormality in an Atypical Presentation of Takayasu Arteritis [abstract]. (Presented Congress of Clinical Rheumatology, Destin FL, May 2019).

7. Spencer et al. Biologic Therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatric Rheumatology (2017) 15:50. DOI 10.1186/s12969-017-0174-0.

8. Dalrymple AM, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Moore T. 14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Diego, Nov 2017).

9. Dalrymple A, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov J, Naides SJ, Moore T. 14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). (Presented Pediatric Rheumatology Symposium (PRSYM), Houston, May 2017).

10. Feller L, Dalrymple AM, Tuttle P IV, Syed RH, Pepmueller P, Moore T. Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).

11. Feller L, Tuttle P IV, Dalrymple AM, Bathula S, Temprano K, Syed RH, Bandlamudi R, Coulson K, Pepmueller P, Moore T. Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented at ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).

12. Feller LS, Tuttle PV, Moore TL: Clinical utility of 14-3-3n in the evaluation of inflammatory arthritis. Arthritis Rheum 66:S170, 2014 (Presented American College of Rheumatology, Boston, MA, November 2014).

13. Feller L, Gilliam B, Cleland E, Syed RH, Pepmueller, PH, Moore TL: Demonstration of antibodies to multiple citrullinated epitopes in the sera of patients with juvenile idiopathic arthritis. Arthritis Rheum 66:S154, 2014 (Presented Pediatric Rheumatology Symposium, Orlando, FL, April 2014).

14. Moore TL, Gilliam BE, Crespo-Pagnussat S, Feller L, Chauhan AK: Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 32:740-746, 2014.

15. Gilliam B, Feller L, Moore TL: IgG anti-cyclic citrullinated peptide antibodies are associated with joint destruction in juvenile idiopathic arthritis patients. Arthritis Rheum 65:S937, 2013 (Presented American College of Rheumatology, San Diego, CA, October 2013).